Medicines are a vital part of modern health care. The question of how to provide patients with access to innovative medicines, in a way that the NHS can afford, has been discussed by policy-makers, politicians and industry for many years.

In 2018, The King’s Fund released a policy report discussing some of the key issues, but the situation is evolving and the National Institute for Health and Care Excellence (NICE) is currently reviewing how it appraises new medicines.

This free online event will explore the current medicines landscape and highlight some of the key challenges to patients accessing medicines in England. The discussion will include patient, industry and system perspectives on the medicines access process and the audience will be invited to send in their own questions to the panel beforehand.

Ahead of the event, send your question to the panel by visiting the Slido page here.

Please submit questions by 12.00pm on Wednesday 10 June for the chance to have your question featured in the discussion. Popular questions submitted during the broadcast on Thursday 18 June will be answered and shared on the event page afterwards.

Presenters

Sally Warren new

Sally Warren

Director of Policy, The King’s Fund

View Bio
Before joining the Fund, Sally had extensive experience in health, care and population health policy and delivery, in central and local government. Sally was Director for Social Care at the Department for Health and Social Care, Director of Programmes at Public Health England and Deputy Chief Inspector (for social care and registration) at the Care Quality Commission. She was also Director at the Cabinet Office, leading a project on social care funding for Budget 2017.

Most recently, Sally worked at the Department for Environment Food and Rural Affairs as Director of the Agri-Food Chain, and latterly Director of EU Exit Preparedness and Response.
Paul Catchpole

Paul Catchpole

Value and Access Director, The Association of the British Pharmaceutical Industry (ABPI)

View Bio

Paul has worked in the healthcare, local government and pharmaceutical sectors for over 30 years. He began his career as an NHS researcher and then held a number of NHS management posts before working on a wide range of UK and international management consultancy assignments at PricewaterhouseCoopers. After moving to Roche, he led work on national reimbursement of medicines, health economics, strategic pricing and market access.

Paul’s policy work at the ABPI over the last nine years includes all aspects of medicines evaluation, health technology assessment, pricing and reimbursement, market access, the Cancer Drugs Fund, biosimilar medicines, EAMS and the Accelerated Access Collaborative. He has led work on shaping and evolving value, access and uptake policy for the pharmaceutical industry in the UK for the last four PPRS negotiations, including the current Voluntary Scheme for Branded Medicines Pricing and Access.

He has a Ph.D in healthcare information systems and is a Member of the British Computer Society and a Chartered Information Technology Professional.

bradley_price

Bradley Price

Policy and Public Affairs Manager, Sarcoma UK

View Bio

Bradley Price is Policy and Public Affairs Manager at Sarcoma UK, the only cancer charity in the UK focusing on all types of sarcoma. He leads the development and implementation of the charity's policy positions, as well as campaigning and influencing work. Bradley specialises in cancer and rare disease policy and commissioning, with a particular interest in access to new medicines. He has previously worked at Prostate Cancer UK and national blood cancer charity Anthony Nolan.


Dominic Pivonka

Head of Health Technology Assessments and Pricing, AbbVie

View Bio

Dominic is Head of Health Technology Assessments (HTA) and Pricing for AbbVie, leading a team in their work with UK HTA bodies to secure patient access for AbbVie’s medicines. Prior to this, he was Head of Market Access Value Propositions for AbbVie and has worked in different market access roles for the last 10 years. Dominic started his career in the pharmaceutical industry in sales before moving into marketing. He holds a bachelor’s degree in environmental sciences and postgraduate degrees in marketing and health economics.


Nina Pinwill

Head of Commercial Operations, NHS England and NHS Improvement

View Bio

Nina Pinwill BSc (Hons) MSc DIC, is the Head of Commercial Operations at NHS England and NHS Improvement and currently Acting Commercial Medicines Director (due to COVID-19) Nina Pinwill leads the commercial operations function within the Commercial Medicines Directorate at NHS England and NHS Innovation. Nina’s role is to ensure that patients have faster access to the most promising new treatments, taxpayers get better value for money in drug expenditure and the route to funding is speeded up for responsibly priced, promising drugs. Nina’s role also includes responsibility for the Cancer Drugs Fund, industry relations, patient access schemes (PAS), the Blueteq prior approval system, dose banding and budget impact tests. Nina is London based.

Nina received her first degree in Geography in 1995 and spent the next five years in various management and planning roles in the Lord Chancellors Department (now the Ministry of Justice). Nina then spent the next 16 years working at the National Institute for Health and Care Excellence (NICE); the independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health in England. Nina has developed and improved various processes at NICE such as the process for technology appraisal and redesigning how NICE choose the topics it produces guidance on. Most recently at NICE Nina’s focus was on the set up, launch and subsequent operation of a new engagement function for the life sciences sector, called the Office for Market Access.

Nina also spent 2015 seconded to the Office for Life Sciences (a joint venture between Department of Health and Social Care and Department for Business, Energy & Industrial Strategy) as a Senior Policy Lead working on the Accelerated Access Review.

Nina gained her MSc in Health Policy from Imperial College London in May 2016 and is a trustee for the Waldenström's Macroglobulinemia UK charity.

Nina’s areas of interest are in strategic planning and developments, leadership, innovative problem solving, effective programme oversight and delivery.

Register

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy and The King’s Fund privacy policy.

Webinars, Webcasts and Virtual Events powered by

Webinars, Webcasts and Virtual Events powered by streamGo